Additionally, we do not use salt bases for our injectable compounds, ensuring a higher quality and more effective treatment for our patients
Common side effects include nausea, vomiting, diarrhea, constipation, and indigestion, particularly during the first few weeks of treatment
Many participants have experienced a decrease of 10% to 20% of their body mass, which is truly encouraging
The clinical trial data does not specifically break down outcomes by immune status, so direct evidence remains limited
Therefore, measurement of GH is not useful to monitor treatment of acromegaly with pegvisomant: instead IGF1 is determined as a surrogate biomarker
These injections are not a quick fix but can play a supportive role in a larger plan